Abstract 1043P
Background
TU2218 is a highly potent, oral dual inhibitor against TGFβ type I receptor (TGFβRI /ALK5) and VEGFR2. VEGF and TGF-β pathways play important roles in the function of TME, especially in immune tolerance inextricably related with poor outcomes of anti-PD-(L)1 therapy. This is a first-in-human study to investigate the safety and tolerability of TU2218 mono- and combination therapy with pembrolizumab.
Methods
This non-randomized, multinational, open-label study has been evaluating the safety, tolerability, PK, and preliminary efficacy of TU2218 mono- and combination therapy with pembrolizumab in advanced solid tumors. The eligible patients were aged ≥ 18 years, ECOG (0 or 1), and had measurable tumors per RECIST 1.1. TU2218 monotherapy was planned at 6 dose levels (30, 60, 105, 150, 195, 270 mg/day) with 2 weeks on and 1 week off in 3-week cycles according to the BOIN method. The starting dose of TU2218 given with pembrolizumab was determined after yielding TRAEs of at least Grade 2 in severity during monotherapy using the traditional 3+3 design.
Results
Seventeen patients with advanced solid tumors received 5 different dose levels of monotherapy. Major demographics, treatment-related adverse events (TRAEs) and PK parameters are summarized in the table.
Table: 1043P
Cohort | 1 | 2 | 3 | 4 | 5 |
Total Daily Dose (mg) | 30 | 60 | 105 | 150 | 195 |
N | 3 | 4 | 4 | 3 | 3 |
Median age (Range) | 54 (48-56) | 61 (46-78) | 70 (52-77) | 72 (56-72) | 65 (37-75) |
Male/ Female | 0/3 | 2/2 | 1/3 | 1/2 | 1/2 |
TRAE, n (Grade) | 0 | 3 (G2) | 2 (G2) | 1 (G2) | 6 (G2) |
* G2 TRAEs were reported from 2 patients of Nausea, Dehydration, Fatigue in Cohort 2, 2 patients of Itching & Platelet Count Decreased in Cohort 3, 1 patient of Nausea in Cohort 4, and 3 patients of Itching, Skin Rash, Myalgia, Anorexia, Arthralgia & Mucositis oral in Cohort 5. | |||||
Mean PK Parameters | |||||
tmax (h) | 1 | 0.7 | 1.6 | 1.2 | |
Cmax (ng/mL) | 95 | 162 | 374 | 781 | 1875 |
AUClast (ng·h/mL) | 200 | 257 | 819 | 1854 | 3664 |
t1/2 (h) | 2.1 | 1.7 | 1.7 | 2.6 | |
* For cohort 5, simulated data |
No TRAEs of Grade 3 or higher were reported while all Grade 2 TRAEs were tolerable in TU2218 monotherapy. Systemic exposure to TU2218 increased over-proportionally with the dose-escalation. The starting dose of TU2218 for the combination therapy with pembrolizumab was 105mg/day, with subsequent incremental doses of 150mg/day and 195mg/day. To date, clinical studies of TU2218 are ongoing.
Conclusions
TU2218, a first-in-class oral dual inhibitor against TGFβRI and VEGFR2, was well-tolerated in the monotherapy.
Clinical trial identification
NCT05204862.
Editorial acknowledgement
Legal entity responsible for the study
TiumBio Co., Ltd.
Funding
TiumBio Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1048P - Phase I/II Study of JK08, an IL-15 antibody fusion protein targeting CTLA-4, with unresectable locally advanced or metastatic cancer
Presenter: Nuria Kotecki
Session: Poster session 19
1049P - Phase Ib/II trial of envafolimab, a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, plus lenvatinib in patients with selected advanced solid tumors
Presenter: Tianshu Liu
Session: Poster session 19
1050P - Sensitization to immunotherapy through manipulation of tumor transcription by lurbinectedin
Presenter: Joan Russo-Cabrera
Session: Poster session 19
1051P - Intratumoral injection of LTX-315 in combination with pembrolizumab in patients with advanced melanoma refractory to prior PD-1/PD-L1 therapy: Interim results from the ATLAS-IT-05 trial
Presenter: Stephane Dalle
Session: Poster session 19
1052P - Phase-Ib trial of metformin combined with nivolumab for refractory/recurrent solid tumors
Presenter: Toshio Kubo
Session: Poster session 19
1053P - Tumor-restricted delivery of an immune-therapeutic payload by modified macrophages for the treatment of glioblastoma: The TEM-GBM STUDY (NCT03866109)
Presenter: Fabio Ciceri
Session: Poster session 19
1054P - A phase Ia study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of a modular CLDN18.2-targeting PG CAR-T therapy (IBI345) in patients with CLDN18.2+ solid tumors
Presenter: Songbing Qin
Session: Poster session 19
1055P - Safety and Activity of SmarT cells plus PD-1 blocking antibodies in patients with heavily pretreated solid cancers: An open-label and dose-escalation study
Presenter: Qin Liu
Session: Poster session 19
1056P - Efficacy of spartalizumab across multiple cancer types in patients with PD1-high mRNA expressing tumors (SOLTI-1904 ACROPOLI)
Presenter: Aleix Prat
Session: Poster session 19
1057P - Long-term follow-up of a phase II study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors
Presenter: Jian Li
Session: Poster session 19